

The Need for an Integrated Computational/Experimental Approach in the Discovery and Design of New Drugs

Pérez-Sánchez H^{1*}, Cecilia JM¹, Imbernón-Tudela B¹, Pérez-Garrido A¹, Soto J¹, Timón-Pérez I¹, García-Rodríguez J², Cano G², Bueno-Crespo A¹ and Vegara-Meseguer J¹

¹Bioinformatics and High Performance Computing Research Group (BIO-HPC), Computer Science Department, Universidad Católica San Antonio de Murcia (UCAM), Campus de los Jerónimos s/n, 30107 Murcia, Spain

²Computing Technology Department, University of Alicante, Ap. 99. E03080. Alicante, Spain

Among all the main problems of haemostasis, we can cite the discovery of novel anticoagulants without side effects. Ever since the discovery of the anticoagulant properties of hirudin from the leech saliva, the increasing relevance of thromboembolic diseases has encouraged a continuous search for new compounds with anticoagulant activity, which has led to the development of the new commercially available anticoagulants [1]. One of the targets for prophylaxis and treatment of thromboembolic diseases is the plasma anticoagulant antithrombin. This protein circulates in blood in a metastable conformation, in which the reactive centre loop is partially inserted and is only activated by heparin and heparan sulfate glycosaminoglycans on the injured subendothelium [2]. Accordingly sulfated polysaccharide heparin chains with different size, from unfractionated to the essential pentasaccharide, have been used with more or less success in anticoagulant therapy and thromboprophylaxis [3]. In the last decades new molecules able to bind antithrombin have been identified. The strategies used in this search have been based mainly on the synthesis or chemical modification of existing drugs, or in the application of natural compounds with similar properties to those currently used [2]. Examples for such compounds are lignins and flavonoids [1,4], highly sulfated small organic ligands that seem to have similar properties to heparins.

Therefore, the discovery of novel or improved drugs for given diseases or special groups of patients, is a very slow and expensive process. Nevertheless, recent results demonstrate the discovery using Virtual Screening (VS) of a novel molecular scaffold [5], different to the previous ones based on heparin. Using this alternate approach, a large database of millions of chemical compounds is screened in-silico and affinity-ranking is used to identify some at least weakly-binding molecules for further refinement. Aided by ever-increasing computational power [3,6,7], VS is an appealing and cost-effective approach to tap into the wealth of available structural information [8,9]. Consequently, novel and enhanced VS methodologies, conveniently exploited in innovative drug discovery strategies can lead to significant and quantifiable developments.

An example of research group that performs drug design and discovery in this direction is the “Bioinformatics and High Performance Computing Research Group (BIO-HPC)”, as stated on their website (<http://bio-hpc.eu>). This research group works in many different but completely related research areas such as:

a) High Performance computing: their research interest includes massively parallel architectures such as Graphics Processing Units, Intel Xeon Phi and Heterogenous processors, as well as bio-inspired algorithms such as Ant Colony Optimization [10], to evaluate the newest frontiers of computing. We are also working in applying these techniques to challenging problems in the fields of Science and Engineering [11,12].

b) Prediction studies of the biological activity of chemical substances by QSAR methods: their work is mainly focused on the search for structural alerts [13,14] for mutagenicity especially less studied for two trials (trials in mammalian cells and in vivo micronucleus studies) but also accepted by the OECD (Organization for Economic Cooperation and Development) for classification of mutagenicity of chemicals. They are also working with several universities to develop predictive QSAR models for different activities (study of antioxidant activity [15] and inhibition of human monoamine oxidase [16]). During this work they also make their contribution to the development of QSAR methodology [17].

c) Advanced Data Clustering Methods: Among the most relevant techniques used for pattern recognition, they develop and apply fuzzy clustering algorithms. These algorithms do not rely on assumptions common to conventional statistical methods, using the theory of fuzzy set. In the literature of fuzzy clustering, the fuzzy c-means (FCM) clustering algorithms defined by Dunn [18] and generated by Bezdek [19] are the well-known methods in cluster analysis. Recently Antonio et al. [20] and Soto et al. [21,22] showed modifications of FCM that improving probabilities in a fuzzy clustering partition. Currently, they are developing their own algorithms for applications in drug discovery, and big data, using HPC.

d) Development and application of Computational Intelligence Methods: Virtual Screening (VS) methods can considerably aid clinical research, predicting how ligands interact with drug targets. However, the accuracy of most VS methods is constrained by limitations in the scoring function that describes biomolecular interactions, and even nowadays these uncertainties are not completely understood. In order to improve accuracy of scoring functions used in most VS methods they propose [23-25] a hybrid novel approach where neural networks (NNET) and support vector machines (SVM) methods are trained with databases of known active (drugs) and inactive compounds, this information being exploited afterwards to improve VS predictions.

*Corresponding author: Pérez-Sánchez H, Bioinformatics and High Performance Computing Research Group (BIO-HPC), Computer Science Department, Universidad Católica San Antonio de Murcia (UCAM), Campus de los Jerónimos s/n, 30107 Murcia, Spain, Tel: 3496827798; E-mail: hperez@ucam.edu

Received December 26, 2013; Accepted December 27, 2013; Published January 03, 2014

Citation: Pérez-Sánchez H, Cecilia JM, Imbernón-Tudela B, Pérez-Garrido A, Soto J, et al. (2014) The Need for an Integrated Computational/Experimental Approach in the Discovery and Design of New Drugs. Drug Des 3: e121. doi:10.4172/2169-0138.1000e121

Copyright: © 2014 Pérez-Sánchez H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

e) Biophysics of Ion Channels: Many physiological properties of undifferentiated mouse embryonic stem cells (mESCs), such as ion channel function, are not fully understood. Ion channels are thought to be involved in cell proliferation and to play an important role in mESCs differentiation. The aim of their study is to characterize functional ion channels [26,27] in cultured undifferentiated mESCs and their role in cell proliferation and differentiation, and apply obtained results to applied projects in drug discovery.

Thus, we consider that in order to make efficient progress in drug discovery areas, a multidisciplinary research group, such as the one described in the previous paragraphs is necessary, and that research groups whose research line(s) are strictly focused on much concreted research areas cannot efficiently contribute to the development of the drug research field.

References

1. Paikin JS, Eikelboom JW, Cairns JA, Hirsh J (2010) New antithrombotic agents-insights from clinical trials. *Nat Rev Cardiol* 7: 498-509.
2. DeAgostini AI, Watkins SC, Slayter HS, Youssoufian H, Rosenberg RD (1990) Localization of anticoagulant active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. *J Cell Biol* 111: 1293-1304.
3. Harenberg J, Wehling M (2008) Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. *Semin Thromb Hemost* 34: 39-57.
4. Gunnarsson GT, Desai UR (2004) Hydrophobic interaction analyses of small organic activators binding to antithrombin. *Bioorg Med Chem* 12: 633-640.
5. Navarro-Fernández J, Pérez-Sánchez H, Martínez-Martínez I, Meliciani I, Guerrero JA, et al. (2012) In silico discovery of a compound with nanomolar affinity to antithrombin causing partial activation and increased heparin affinity. *J Med Chem* 55: 6403-6412.
6. Pérez-Sánchez H, Wenzel W (2011) Optimization methods for virtual screening on novel computational architectures. *Curr Comput Aided Drug Des* 7: 44-52.
7. Guerrero GD, Pérez-Sánchez H, Cecilia JM, García JM (2012) Parallelization of Virtual Screening in Drug Discovery on Massively Parallel Architectures. Parallel, Distributed and Network-Based Processing (PDP), 2012 20th Euromicro International Conference on 588-595.
8. Henry BL, Connell J, Liang A, Krishnasamy C, Desai UR (2009) Interaction of antithrombin with sulfated, low molecular weight lignins: opportunities for potent, selective modulation of antithrombin function. *J Biol Chem* 284: 20897-20908.
9. Ghosh S, Nie A, An J, Huang Z (2006) Structure-based virtual screening of chemical libraries for drug discovery. *Curr Opin Chem Biol* 10: 194-202.
10. Cecilia JM, García JM, Nisbet A, Amos M, Ujaldón M (2013) Enhancing data parallelism for ant colony optimization on gpus. *Journal of Parallel and Distributed Computing* 73: 42-51.
11. Hernández M, Guerrero GD, Cecilia JM, García JM, Inuggi A, et al. (2013) Accelerating fibre orientation estimation from diffusion weighted magnetic resonance imaging using GPUs. *PLoS One* 8: e61892.
12. Sánchez-Linares I, Pérez-Sánchez H, Cecilia JM, García JM (2012) High-Throughput parallel blind Virtual Screening using BINDSURF. *BMC Bioinformatics* 13 Suppl 14: S13.
13. Pérez-Garrido A, Helguera AM, López GC, Cordeiro MN, Escudero AG (2010) A topological substructural molecular design approach for predicting mutagenesis end-points of alpha, beta-unsaturated carbonyl compounds. *Toxicology* 268: 64-77.
14. Pérez-Garrido A, Girón-Rodríguez F, Helguera AM, Borges F, Combes RD (2013) Topological structural alerts modulations of mammalian cell mutagenicity for halogenated derivatives. *SAR QSAR Environ Res*.
15. Pérez-Garrido A, Helguera AM, Ruiz JM, Rentero PZ (2012) Topological substructural molecular design approach: radical scavenging activity. *Eur J Med Chem* 49: 86-94.
16. Helguera AM, Pérez-Garrido A, Gaspar A, Reis J, Cagide F, et al. (2013) Combining QSAR classification models for predictive modeling of human monoamine oxidase inhibitors. *Eur J Med Chem* 59: 75-90.
17. Pérez-Garrido A, Helguera AM, Borges F, Cordeiro MN, Rivero V, et al. (2011) Two new parameters based on distances in a receiver operating characteristic chart for the selection of classification models. *J Chem Inf Model* 51: 2746-2759.
18. Duda RO, Hart PE (1973) *Pattern Classification and Scene Analysis*, Wiley, New York.
19. Bezdek JC (1981) "Pattern Recognition with Fuzzy Objective function Algorithms", Plenum Press, New York.
20. Flores-Sintas A, Cadenas J, Martin F (1998) A local geometrical application to fuzzy clustering. *Fuzzy Sets and Systems* 100: 245-256.
21. Soto J, Isabel VAM, Flores-SA (2007) A fuzzy clustering application to precise orbit determination. *J Comput Appl Math* 204:137-143.
22. Soto J, Flores-SA, Palarea-AJ (2008) Improving probabilities in a fuzzy clustering partition. *Fuzzy Sets and Systems* 159: 406-421.
23. Pérez-SH, Cano G, García-RJ (2013) Improving Drug Discovery using Hybrid Softcomputing Methods. *Applied Soft Computing*.
24. Cano G, García-RJ, Pérez-SH (2014) Improvement of Virtual Screening predictions using Computational Intelligence methods. *Letters in Drug Design and Discovery* 11: 33-39.
25. Bueno-Crespo A, García-Laencina PJ, Sancho-Gómez JL (2013) Neural architecture design based on extreme learning machine. *Neural Netw* 48: 19-24.
26. Vegara-Meseguer JM, Soria-Escoms B (2003) Ion channels in the plasma membrane of mouse embryonic stem cell. *European Biophysics Journal* 32: 318.
27. Vaca P, Martín F, Vegara-Meseguer JM, Rovira JM, Berná G, et al. (2006) Induction of differentiation of embryonic stem cells into insulin-secreting cells by fetal soluble factors. *Stem Cells* 24: 258-265.